MAP2K7 and cholangiocarcinoma: Furthermore, there is also reported the combinational therapy of SMKIs with MEK blockers, such as pazopanib and trametinib, respectively, as well as the use of another MEK blocker, selumetinibis also studied for CCA [63,64].